No "Japan pharma for sale signs," by P Reed Maurer

18 December 2012

Want to acquire a Japanese pharmaceutical company? Join the back of a long line of companies with the same objective. There is no shortage of willing buyers, but trying to find a willing seller is like looking for a needle in a haystack, says P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL) in an exclusive article for The Pharma Letter.

The situation is succinctly described by the following quotation: “The only investment barrier to Japan for Western pharmaceutical companies since 1975 is their inability to make attractive acquisitions,” he notes.

Below is the chronology of “Out/In” deals since the first two in 1983. This does not include
foreign company buy-outs of joint ventures. Please note:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >